Home Latest Headlines

Latest Headlines

Multiple Myeloma Care in Latin America

Two studies that assessed multiple myeloma (MM) care in Latin America found significant differences in access and outcomes between public and private health care institutions. Both...

How Have Improvements in Myeloma Care Impacted Costs?

A study published in the European Journal of Haematology calculated costs and survival outcomes associated with implementation of new early-line treatments for multiple myeloma (MM). For this...

Patients with MM Report Lower QOL Compared with Other Cancer Types

A study published in BMC Medicine evaluated physical and mental health-related outcomes in patients with multiple myeloma (MM) compared with patients without cancer. For this study, the...

Caregiver Burden of Outpatient AHCT for Multiple Myeloma

A study published in Clinical Lymphoma, Myeloma & Leukemia evaluated the burden of outpatient autologous hematopoietic cell transplantation (AHCT) on caregivers of patients with multiple myeloma (MM). “The application of different...

Cost Burden of Proteasome Inhibitors for Multiple Myeloma

A study published in the Journal of Medical Economics calculated costs associated with the use of different proteasome inhibitors (PI) for the treatment of patients with...

Melflufen Combination Approved for Heavily Pretreated MM

On March 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (melflufen) in combination with dexamethasone for the treatment...

Daratumumab Monotherapy Safe in Heavily Treated Relapsed or Refractory Multiple Myeloma

An early access treatment protocol (EAP) found that daratumumab monotherapy was safe in a population of patients with heavily treated relapsed or refractory multiple...

Economic Burden of Late-Stage MM Treatment

A study published online in the Journal of Oncology Pharmacy Practice calculated economic outcomes of patients with relapsed/refractory multiple myeloma (RRMM) in the first year following...

Nearly Half of Patients with Multiple Myeloma Die in the Hospital

Findings presented at the ASH 2020 Annual Meeting & Exposition found that almost half of patients with multiple myeloma (MM) die in the hospital,...

KarMMA: BCMA CAR-T Spurs Lasting Remission in Relapsed/Refractory MM

The latest updates from the KarMMA trial, published in The New England Journal of Medicine, showed that treatment with idecabtagene vicleucel (ide-cel) for relapsed/refractory...